Hon, KL;
Leung, KKY;
Leung, AK;
Qian, SY;
Chan, VP;
Ip, P;
Wong, IC;
(2020)
Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.
Drugs Context
, 9
10.7573/dic.2020-4-15.
Preview |
Text
dic-2020-4-15.pdf - Published Version Download (424kB) | Preview |
Abstract
Many viral respiratory infections can cause severe acute respiratory symptoms leading to mortality and morbidity. In the spring of 2003, the severe acute respiratory syndrome (SARS) outbreak caused by SARS-CoV spread globally. In the summer of 2012, the Middle East respiratory syndrome (MERS) outbreak caused by MERS-CoV occurred in Saudi Arabia. In the winter of 2019, the coronavirus disease 2019 (COVID-19) outbreak caused by a novel coronavirus SARS-CoV-2 occurred in China which rapidly spread worldwide causing a global pandemic. Up until 27 May 2020, there are 5.5 million confirmed cases of COVID-19 and 347,587 COVID-19 related deaths worldwide, and there has also been an unprecedented increase in socioeconomic and psychosocial issues related to COVID-19. This overview aims to review the current developments in preventive treatments and therapies for COVID-19. The development of vaccines for SARS-CoV-2 is ongoing and various clinical trials are currently underway around the world. It is hoped that existing antivirals including remdesivir and lopinavir-ritonavir might have roles in the treatment of COVID-19, but results from trials thus far have not been promising. COVID-19 causes a mild respiratory disease in the majority of cases, but in some cases, cytokine activation causes sepsis and acute respiratory distress syndrome, leading to morbidity and mortality. Immunomodulatory treatments and biologics are also being actively explored as therapeutics for COVID-19. On the other hand, the use of steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) has been discouraged based on concerns about their adverse effects. Over the past two decades, coronaviruses have caused major epidemics and outbreaks worldwide, whilst modern medicine has been playing catch-up all along.
| Type: | Article |
|---|---|
| Title: | Coronavirus disease 2019 (COVID-19): latest developments in potential treatments |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.7573/dic.2020-4-15 |
| Publisher version: | http://dx.doi.org/10.7573/dic.2020-4-15 |
| Language: | English |
| Additional information: | Copyright © 2020 Hon KL, Leung KKY, Leung AKC, Qian SY, Chan VPY, Ip P, Wong ICK. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission. |
| Keywords: | COVID-19, SARS-CoV-2, coronavirus, review, therapeutics, vaccines |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10105366 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
